FATE News and Press, Fate Therapeutics Inc. From 06/09/20

Shares of Fate Therapeutics (NASDAQ: FATE) gained over 18% last month, according to data provided by S&P Global Market Intelligence . Most of the stock's gains in May can be traced to a single announcement by the cell-therapy developer.  On May 20, the development-stage company an...

Shares of Fate Therapeutics (NASDAQ: FATE) were up 19% to $33.73 at 1:39 p.m. EDT on Tuesday after the company raised at least $214 million through a public secondary offering and a private placement with Johnson & Johnson (NYSE: JNJ) . Fate sold 6,181,562 shares at $28.31 in the p...

Fate Therapeutics (NASDAQ: FATE ) has priced its public offering of 6,181,562 common shares at $28.31/share, for an aggregate offering of ~$175M. More news on: Fate Therapeutics, Inc., Healthcare stocks news, , Read more ...

The FDA has cleared Fate Therapeutics' (NASDAQ: FATE ) Investigational New Drug (IND) application for FT538, the first CRISPR-edited, iPSC-derived cell therapy. More news on: Fate Therapeutics, Inc., Read more ...

Phase 1 Clinical Study to Evaluate Multiple Doses of FT538 as Monotherapy for Acute Myeloid Leukemia and in Combination with Anti-CD38 Monoclonal Antibody Therapy for Multiple Myeloma Off-the-shelf NK Cell Product Candidate Derived from Clonal Master iPSC Line Engineered with Three Fu...

Investing in gene therapy companies is no doubt an exciting venture. Indeed, sector players are rapidly making progress in combating rare or difficult to treat diseases that traditional chemical based drugs simply cannot accomplish. While the market for such novel treatments is still young, it ...

Unlike many other mid-cap biotech companies, shares of Fate Therapeutics (NASDAQ: FATE) are almost entirely owned by institutional investors. Just what exactly does the company have in its pipeline that could entice so much interest from smart money?  As of now, over 90% of the company...

Image source: The Motley Fool. Fate Therapeutics Inc   (NASDAQ: FATE) Q1 2020 Earnings Call May 11, 2020 , 5:00 p.m. ET Operator Continue reading

Biotech Pulse Source: COVID-19 image by Getty Images; edits by PrudentBiotech.com It has taken a pandemic for biotechs to take flight towards their all-time high. One of the first industry groups to recover from the virus-related selloff and be neutral for the year, biotech indexes hav...

Fate Therapeutics, Inc. (FATE) Q1 2020 Earnings Conference Call May 11, 2020 5:00 PM ET Company Participants Scott Wolchko - President & Chief Executive Officer Wayne Chu - Senior Vice President, Clinical Development Conference Call Participants Ted Tenthoff - Piper Sandl...